Open sidebar
Focus
Paxlovid
COVID Treatments & Remedies
|
Zachary Stieber
One in Five Pfizer Drug Users Experience COVID-19 Rebound: Study
Many Paxlovid recipients have suffered from renewed symptoms.
Nov 14, 2023
|
Zachary Stieber
Nov 14
|
Long COVID
|
Naveen Athrappully
Paxlovid Does Not Work Against 'Long COVID': Study
Out of the 31 long COVID conditions, Paxlovid was found to minimize the incidence of only one.
Oct 31, 2023
|
Naveen Athrappully
Oct 31
|
Companies
|
Naveen Athrappully
Pfizer to Charge Nearly $1,400 for COVID-19 Drug Paxlovid
Pfizer projects Paxlovid sales to fall by 58 percent this year compared to 2022.
Oct 19, 2023
|
Naveen Athrappully
Oct 19
|
COVID Treatments & Remedies
|
Aldgra Fredly
Study Finds Paxlovid, Molnupiravir Reduce Omicron Hospitalization, Mortality
Researchers said that both oral antiviral drugs can be used to treat nonhospitalized patients at high risk of progressing to severe COVID-19.
Sep 22, 2023
|
Aldgra Fredly
Sep 22
|
Viewpoints
|
Maryanne Demasi
FDA Head Admits ‘Cheerleading’ Pfizer’s Drug Paxlovid
Aug 23, 2023
|
Maryanne Demasi
Aug 23
|
Business & Markets
|
Tom Ozimek
Ex-Pfizer Employee Faces Insider-Trading Charges on COVID-19 Drug Trial
Jul 03, 2023
|
Tom Ozimek
Jul 03
|
American Thought Leaders
|
Jan Jekielek
Dr. Flavio Cadegiani: From ‘Sciencesplaining’ to Collective Gaslighting, the COVID Pandemic Resulted In a Loss of Compassion
Jul 01, 2023
|
Jan Jekielek
Jul 01
|
COVID Treatments & Remedies
|
Jane Nguyen
FDA Approves Pfizer’s Paxlovid to Treat COVID-19
May 29, 2023
|
Jane Nguyen
May 29
|
Health & Safety
|
Naveen Athrappully
Pfizer's COVID Pill Paxlovid Inching Closer to Getting FDA Approval
Mar 17, 2023
|
Naveen Athrappully
Mar 17
|
WORLD
|
Naveen Athrappully
US Begins Trials for Japanese COVID-19 Antiviral Drug Xocova
Feb 16, 2023
|
Naveen Athrappully
Feb 16
|